Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era

Level 1 evidence supports a survival benefit to cytoreductive nephrectomy (CN) followed by cytokine therapy in patients with metastatic renal cell carcinoma (mRCC) [1 –3]. Although comparable randomized data do not exist for patients treated with targeted therapies, several retrospective studies suggest a similar survival benefit for CN [4–6]. However, it is unclear whether selection criteria and treatment sequencing paradigms developed during the immunothera py era are applicable to patients treated within the contemporary targeted therapy era.
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research